Screener / SEC EDGAR /CIK 0000882796 /10-K filed Feb 26, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Biocryst Pharmaceuticals Inc BCRX

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of BCRX's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Dec 14, 2021
Questions asked 3 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 2 UPLOAD
  2. 2. Questions in them 3 numbered comments
  3. 3. Company replies 2 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 35 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2020

2021-12-14 to 2022-01-18 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2022-01-18
Notes to Consolidated Financial Statements · Note 3. Royalty Monetizations, page 64
SEC asked
We see that you used level 3 inputs to determine the fair value of the ORLADEYO royalty financing obligation. Please tell us where you provided all of the relevant disclosures required by ASC 820-10-50, including quantitative information about the significant unobservable inputs used in the fair value measurement.
BCRX answered
The Company acknowledges the Staff’s comment and respectfully informs the Staff that the ORLADEYO® royalty financing obligation was recorded at fair value as of the transaction date but is then recorded at its carrying value in subsequent periods. As the disclosure requirements in ASC 820 are focused solely on fair value measurements recorded subsequent to the initial recognition, we determined the relevant disclosures of ASC 820-10-50 are not applicable.

As disclosed in

Note 3, the Company recorded the ORLADEYO financing obligation at fair value at the time of the transaction (December 7,
Rest of the answer

2020) based on estimated future royalties due, which were based on level 3 unobservable inputs. However, the financing obligation is subsequently recorded at its carrying value in accordance with ASC 470 based on the application of the effective interest method. ASC 470 requires amounts recorded as debt to be amortized under the interest method, and accordingly, the Company determines the effective interest rate based on future royalty payments to be made to the counterparty. In applying the effective interest method, if there is a change in estimated cash flows from future revenue, the Company utilizes the prospective method to periodically assess and adjust the carrying value based on estimated future cash payments. At December 31, 2020, there were no changes to the estimated future cash royalty payments used in the initial estimate to record the fair value as of the transaction date of December 7, 2020.

For clarity, the

Company will revise future filings to include the following enhanced disclosure relative to the ongoing accounting treatment:

The fair value for the royalty financing obligation at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligation at its carrying value using the effective interest method. In order to amortize the royalty financing obligation, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligation and the effective interest rate.

If you have any additional questions or comments or require further information with respect to the foregoing, please call the undersigned at (919) 859-7930 or Brian

Lane of Gibson, Dunn & Crutcher LLP at (202) 887-3646.

Read in the reply
In its next report

First report after the company's reply of Jan 14, 2022: 10-K filed Feb 28, 2022 ↗, against the 10-K filed Mar 1, 2021 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2022-01-18

Form S-3

2020-04-27 to 2020-05-04 · 2 questions · 1 letter from the SEC, 1 from the company
No closing letter
Risk factorsLegal and contingenciesDerivatives and hedging
SEC asked (1)
We note your disclosure on page 6 regarding the exclusive forum provision in your bylaws. Please include a risk factor on this exclusive forum provision that discusses the risks and implications of the provision. In addition to any other material risks, please discuss any potential costs, unfavorable rulings, or uncertainty with regard to enforcement. In this regard, please refer to our comment below.
BCRX answered
In the future, the Company will include a risk factor addressing this provision and these limitations in the “Risk Factors” section of its periodic reports filed pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”). More specifically, in the Company’s quarterly report for the quarter ended March 31, 2020, the Company will include a risk factor in substantially the following form:

“Our Amended and Restated Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain litigation that may be initiated by our
Rest of the answer

stockholders, which may limit a stockholder’s ability to obtain a favorable judicial forum for such disputes with us or our directors, officers or employees.

Our Amended and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, stockholders, employees or agents to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents arising out of or relating to any provision of the General Corporation Law of Delaware or our Certificate of Incorporation or Amended and Restated Bylaws or (iv) any action against us or any of our directors, officers, stockholders, employees or agents governed by the internal affairs doctrine of the State of Delaware. This exclusive forum provision does not apply to establish the Delaware Court of Chancery as the forum for actions or proceedings brought to enforce a duty or liability created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.

This exclusive forum provision may limit a stockholder’s ability to choose its preferred judicial forum for disputes with us or our directors, officers, employees or agents, which may discourage the filing of lawsuits with respect to such claims. If a court were to find this exclusive forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in another jurisdiction, which could adversely affect our business and financial condition.”

Read in the reply
Descriptio of Common Stock, Preferred Stock and Depositary Shares, page 6
SEC asked (2)
We note that your forum selection provision discussed in your disclosure here and in Article 8 of your bylaws identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any "derivative action." Please disclose whether this provision applies to actions arising under the Exchange Act and the Securities Act.
Rest of the question

We note in this regard that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules or regulations thereunder. If this provision does not apply to actions arising under the Exchange Act, please tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Exchange Act. If you intend for this provision to apply to the Securities Act, please also revise your prospectus to state that there is uncertainty as to whether a court would enforce such provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.

BCRX answered
The forum selection provision in the Company’s Amended and Restated Bylaws does not apply to establish the Delaware Court of Chancery as the forum for actions or proceedings brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Exchange Act. Accordingly, when the Company files a prospectus supplement pursuant to Rule 424 under the Securities Act in connection with any future offering under the Registration Statement, it will include in the base prospectus included therein the following disclosure under the heading “Description of Capital
Rest of the answer

Stock”:

“Exclusive Forum for Certain Actions

Our Amended and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, stockholders, employees or agents to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents arising out of or relating to any provision of the General Corporation Law of Delaware or our Certificate of Incorporation or Amended and Restated Bylaws or (iv) any action against us or any of our directors, officers, stockholders, employees or agents governed by the internal affairs doctrine of the State of Delaware. Our Bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock will be deemed to have notice of and to have consented to this choice of forum provision. This exclusive forum provision does not apply to establish the Delaware Court of Chancery as the forum for actions or proceedings brought to enforce a duty or liability created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.

This exclusive forum provision may limit a stockholder’s ability to choose its preferred judicial forum for disputes with us or our directors, officers, employees or agents, which may discourage the filing of lawsuits with respect to such claims. If a court were to find this exclusive forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in another jurisdiction, which could adversely

***

If you have any additional questions or comments or require further information with respect to the foregoing, please call the undersigned at (919) 859-7930 or Robyn Zolman of Gibson, Dunn & Crutcher LLP at (303)

298-5740.

Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
6 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 11 letters filed since 2016-04-14. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.